Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization-Heart Failure (CARE-HF) trial

European Journal of Heart Failure

Volumn 14, Issue 6, 2012, Pages 628-634

  Cleland, John G F ^a   Freemantle, Nick ^b   Erdmann, Erland ^c   Gras, Daniel ^d   Kappenberger, Lukas ^e   Tavazzi, Luigi ^f   Daubert, Jean Claude ^g  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF COLOGNE   (Germany)

^d Nouvelles Cliniques Nantaises   (France)

^e UNIVERSITY OF LAUSANNE   (Switzerland)

^f MARIA CECILIA HOSPITAL   (Italy)

^g PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Cardiac resynchronization therapy; Heart failure; Randomized trial

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; LOOP DIURETIC AGENT; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CARDIAC PATIENT; CARDIAC RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; CARDIOVASCULAR PARAMETERS; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; END SYSTOLIC VOLUME INDEX; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMPLANTATION; INFORMED CONSENT; INTERVENTRICULAR MECHANICAL DELAY; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; MORTALITY; PRIORITY JOURNAL; QRS COMPLEX; RANDOMIZED CONTROLLED TRIAL; SURVIVOR; SYSTOLIC BLOOD PRESSURE; TREATMENT REFUSAL;

AGED; CARDIAC PACING, ARTIFICIAL; CARDIAC RESYNCHRONIZATION THERAPY; CONFIDENCE INTERVALS; FEMALE; FRANCE; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STATISTICS AS TOPIC; STROKE VOLUME; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 84861565228     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfs055     Document Type: Article

References (25)

1. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Messenger Jfor the MIRACLE Study Group. Cardiac resynchronisation in chronic heart failure. N Engl J Med 2002;346: 1845-1853.
2. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, Demets D, White BG, DeVries DW, Feldman AMComparison of Medical Therapy, Pacing, Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-2150.
3. Cleland JGF, Daubert J-C, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi Lfor the Cardiac Resynchronisation-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-1549.
4. Cleland JGF, Daubert J-C, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L, on behalf of the CARE-HF study investigators. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the Cardiac Resynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 2006;27:1928-1932.
5. Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, McMurray J, Ponikowski P, Priori SG, Sutton R, Van Veldhuisen DJ. 2010 Focused update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur J Heart Fail 2010;12:1143-1153.
6. Van Veldhuisen DJ, Maas AH, Priori SG, Stolt P, van Gelder IC, Dickstein K, Swedberg K. Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter defibrillator) for patients with heart failure in Europe: changes from 2004 to 2008. Eur J Heart Fail 2009;11: 1143-1151.
7. Yao G, Freemantle N, Calvert M, Bryan S, Daubert J-C, Cleland JGF. The longterm cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J 2007;28:42-51.
8. Feldman AM, de LG, Bristow MR, Saxon LA, De MT, Kass DA, Boehmer J, Singh S, Whellan DJ, Carson P, Boscoe A, Baker TM, Gunderman MR. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005;46:2311-2321.
9. Cleland JGF, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Klein W, Tavazzi L; CARE-HF study Steering Committee and Investigators. The CARE-HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end-points. Eur J Heart Fail 2001;3:481-489.
10. Cleland JG, Daubert J-C, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L, CARE-HF Study Steering Committee and Investigators. Baseline characteristics of patients recruited into the CARE-HF study. Eur J Heart Fail 2005;7: 205-214.
11. Tang AS,Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010;363:2385-2395.
12. Linde C, Abraham WT, Gold MR, St. John Sutton M, Ghio S, Daubert J-C, on behalf of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) Study. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008;52:1834-1843.
13. Daubert J-C, Gold MR, Abraham WT, Ghio S, Hassager C, Goode G, Szili-Torok T, Linde C, on behalf of the REVERSE Study Group. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction. J Am Coll Cardiol 2009; 54:1837-1846.
14. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA 3rd, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D,Zareba W; MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329-1338.
15. Cleland JG, Coletta A, Buga L, Antony R, Pellicori P, Freemantle N, Clark AL. Clinical trials update from the American Heart Association Meeting 2010: EMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF and PROTECT. Eur J Heart Fail 2011;13;460-465.
16. Ghio S, Freemantle N, Scelsi L, Serio A, Magrini G, Pasotti M, Shankar A, Cleland JGF, Tavazzi L. Long term left ventricular reverse remodelling with cardiac resynchronization therapy. Results from the CARE-HF trial. Eur J Heart Fail 2009;11:480-488.
17. Cleland JG, Freemantle N, Ghio S, Fruhwald F, Shankar A, Marijianowski M, Verboven Y, Tavazzi L. Predicting the long-term effects of cardiac resynchronisation therapy on mortality from baseline variables and the early response: a report from CARE-HF (Cardiac Resynchronisation in Heart Failure). J Am Coll Cardiol 2008;52:438-445.
18. Foley PW, Chalil S, Khadjooi K, Irwin N, Smith RE, Leyva F. Left ventricular reverse remodelling, long-term clinical outcome, and mode of death after cardiac resynchronization therapy. Eur J Heart Fail 2011;13:43-51.
19. Solomon SD, Foster E, Bourgoun M, Shah A, Viloria E, Brown MW, Hall WJ, Pfeffer MA, Moss AJ. Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: multicenter automatic defibrillator implantation trial: cardiac resynchronization therapy. Circulation 2010;122:985-992.
20. Wikstrom BG, Lundqvist CB, Andren B, Lonnerholm S, Blomstrom P, Freemantle N, Remp T, Cleland JG. The effects of aetiology on outcome in patients treated with cardiac resynchronisation therapy in the CARE-HF trial. Eur Heart J 2009;30:782-788.
21. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA III, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329-1338.
22. Bogale N, Dickstein K, Priori S, Auricchio A, Brugada J, Cleland JG, Derumeaux G, Gitt A, Gras D, Komajda M, Linde C, Morgan J, Van Veldhuisen D. European Cardiac Resynchronisation Therapy (CRT) survey: rationale and design. Eur J Heart Fail 2009;11:326-330.
23. Dickstein K, Bogale N, Priori S, Auricchio A, Cleland JGF, Gitt A, Limbourg T, Linde C, Van Veldhuisen DJ, Brugada J, on behalf of the Scientific Committee and National Coordinators. The European Cardiac Resynchronization Therapy Survey. Eur Heart J 2009;30:2450-2460.
24. Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohasci P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL, for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-1658.
25. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Witte J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717.